---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115900"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:44:42.948558+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocugen closes $30M credit facility with Avenue Capital; proceeds for clinical development

## Summary
- Term loans of $30M fully funded on Nov 6, 2024; maturity Nov 1, 2028; interest rate prime + 4.25% (floor at closing prime).
- Up to $6M of principal convertible into common stock at 80% of trading price; conversion capped at 19.9% of outstanding shares.
- Issued 1,056,338 shares to Lenders under Subscription Agreement; registration statement to be filed within 90 days.
- Proceeds to support OCU400 Phase 3 liMeliGhT trial and BLA/MAA submissions; cash runway extends into Q1 2026.
- Loan secured by all assets; negative pledge on IP; prepayment premiums from 3% down to 0.5% over time.

## SEC filing metadata
- accession: 0001104659-24-115900
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465924115900/0001104659-24-115900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465924115900/tm2427800d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115900
- JSON: https://secwatch.observer/filing/0001104659-24-115900.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.